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Abstract
Previously, we have shown the loss of anti-Bax function in Creutzfeldt Jakob disease (CJD)-associated prion protein (PrP)
mutants that are unable to generate cytosolic PrP (CyPrP). To determine if the anti-Bax function of PrP modulates the
manifestation of prion diseases, we further investigated the anti-Bax function of eight familial Gerstmann-Stra ¨ussler-
Scheinker Syndrome (GSS)-associated PrP mutants. These PrP mutants contained their respective methionine (
M) or valine
(
V) at codon 129. All of the mutants lost their ability to prevent Bax-mediated chromatin condensation or DNA
fragmentation in primary human neurons. In the breast carcinoma MCF-7 cells, the F198S
V, D202N
V, P102L
V and Q217R
V
retained, whereas the P102L
M, P105L
V, Y145stop
M and Q212P
M PrP mutants lost their ability to inhibit Bax-mediated
condensed chromatin. The inhibition of Bax-mediated condensed chromatin depended on the ability of the mutants to
generate cytosolic PrP. However, except for the P102L
V, none of the mutants significantly inhibited Bax-mediated caspase
activation. These results show that the cytosolic PrP generated from the GSS mutants is not as efficient as wild type PrP in
inhibiting Bax-mediated cell death. Furthermore, these results indicate that the anti-Bax function is also disrupted in GSS-
associated PrP mutants and is not associated with the difference between CJD and GSS.
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Introduction
Autosomal dominant inherited prion protein (PrP) gene muta-
tions cause approximately 10% of all prion diseases [1]. Eleven
different single point mutations are associated with Creutzfeldt-
Jakob disease (CJD), eight different single point mutations are
associated with Gerstmann-Strau ¨ssler-Scheinker (GSS), and the
D178N mutation causes Fatal Familial Insomnia (FFI) [2–4]. Each
mutation is specifically associated with either a methionine or a
valine polymorphic amino acid at codon 129, which can severely
affect the type, the onset and the duration of the disease [4]. While
each of the PrP single point mutations is sufficient for neurodegen-
eration, the onset and duration of disease, the area of the brain
affected and the pathology associated with neurodegeneration
distinguish each ofthesediseases.CJD,characterizedbyspongiform
encephalopathy, astrogliosis, and proteinase K resistant PrP in the
cerebral cortex, generates a rapidly progressing dementiainaffected
individuals [3,4]. FFI affects the ventral thalamic area and the
primary symptoms are insomnia followed by a rapidly progressing
dementia of short duration [5]. GSS, characterized by astrogliosis,
proteinase K resistant PrP, PrP-plaques, and sometimes spongiform
encephalopathy and neurofibrillary tangles, is associated with ataxia
and/or spastic paraparesis [2,6]. GSS occurs in the fifth or sixth
decade of life and, in contrast to CJD, the progression of the disease
is slow [1].
The underlying molecular mechanism of prion diseases
associated with each of these mutations is unclear. Gain of
function is suspected as the cause of the disease. However, while
the mutant proteins are expressed throughout the lifespan of the
individual, disease rarely develops before the fourth or fifth decade
of life, indicating that misfolding of PrP caused by the mutation is
not sufficient to initiate the neurodegeneration. This prompted us
to investigate if loss of function could be involved in the length and
severity of disease progression.
While the normal function of PrP is still not entirely clear, there
is growing evidence for the neuroprotective roles of PrP [7,8]. PrP
null hippocampal neuronal cell lines and PrP null mice have
increased susceptibility to a variety of insults [9–13]. Furthermore,
recent evidence indicates that PrP prevents cell death in cancer cell
types. PrP prevents apoptosis in multidrug-resistant breast and
gastric carcinoma cells [14–17]. We have reported that the normal
cellular prion protein prevents Bax-mediated cell death in primary
human neurons and in the breast carcinoma MCF-7 cell line [18–
20]. Bax, a member of the Bcl-2 family of proteins, is a strong pro-
apoptotic protein in neurons [21]. Bax is normally cytosolic or
loosely attached to mitochondria but, in cells submitted to
apoptotic insults, Bax undergoes a change in conformation,
oligomerisation, translocation to the mitochondria and then
induces the release of apoptogenic factors from the mitochondria
into the cytosol [22]. The release of cytochrome c in the cytosol
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Caspase-3 (Casp3) activation and caspase-dependent DNA
fragmentation into 180 bp fragments and condensed chromatin
[23]. The mitochondria-released apoptosis inducing factor (AIF)
and endonuclease G (Endo G) directly translocate to the nucleus
and activate caspase-independent DNA fragmentation in large
50 Kb fragments and condensed chromatin [24,25]. PrP prevents
the conformational change of Bax and thus acts at the very first
step of Bax activation [18]. While most of the PrP accumulates on
the cell surface as a GPI-anchored protein, it is the smaller amount
of cytosolic PrP (CyPrP) that is responsible for the anti-Bax
function [19,26]. CyPrP can arise from either retrotranslocation of
PrP from the secretory pathway or via a failure of PrP’s signal
peptide to integrate into the endoplasmic reticulum during protein
synthesis (pre-emptive quality control pathway) [19,27–29].
Moreover, the anti-Bax function of PrP is situated within helix 3
of PrP, the area with the most single point mutations in PrP
diseases [30].
We previously showed that the GSS-associated A117V PrP
mutant with a valine at codon 129 retained the anti-Bax function
while all of the 11 CJD-associated PrP mutations carrying a
methionine at codon 129 or the FFI-associated D178N PrP
mutant lost the ability to prevent Bax-mediated condensed
chromatin in human neurons [31]. Considering that GSS disease
has a slower progression and a later onset compared to CJD, we
investigated whether all other GSS-associated PrP mutants
retained the anti-Bax function.
Materials and Methods
Cell cultures
Cultures of human primary neurons were done as previously
described under the ethical approval from the McGill University
Institutional Review Board [32]. Mouse neuroblastoma N2a cells
and human MCF-7 breast carcinoma cells were obtained from
The American Type Culture Collection (Manassas, VA, USA) and
cultured as described previously [30].
Cloning, site-directed mutagenesis of human PrP, and
sequencing of PrP mutants
GSS-associated mutations were produced by QuikChange Site-
Directed Mutagenesis (Invitrogen, Burlington, ON, Canada) from
the pcDNA3.1(+)-PrP wild type carrying a valine (WT PrP
V)o ra
methionine (WT PrP
M) at the polymorphic codon 129 [31].
Forward primers used to produce PrP mutants P102L
M, P102L
V,
P105L
V, Y145stop
M, F198S
V, D202N
V, Q212P
M, and Q217R
V
are the following: F198S, 59-AGGGGGAGAACTCCACCGA-
GACCGAC-39; D202N, 59-GAACTTCACCGAGACCAACGT-
TAAGATGATGGAG-39; Q217R, 59-CAGATGTGTAT CAC-
CCGGTACGAGAGGGAATCTC-39; P102L, 59-GTCAGTGG-
AACAAGCTGAGTAAGC CAAAAACC-39; P105L, 59-GGA
ACAAGCCGAGTAAGCTAAAAACCAACATGAAGCAC-39;
Y145stop, 59-CGGCAGTGACTAGGAGGATCGTTACTATC-
G-39; and Q212P, GCGTGGTTGAGCC GATGTGTATCA-
CCC. All PrP mutations were confirmed by sequencing using the
Sequenase Version 2.0 DNA Sequencing kit (USB, Cleveland,
OH, USA) and the polymorphism at codon 129 was confirmed by
PCR [31]. As previously done for WT PrP, PrP mutant cDNAs
were PCR amplified and cloned downstream of the cytomegalo-
virus (CMV) promoter of the pBudCE4.1 bigenic vector
containing the enhanced green fluorescent protein (EGFP) or
EGFP-Bax cDNAs under the elongation factor 1a (EF-1a)
promoter [18]. The PCR amplified PrP mutants were cloned into
the Sca I and Xba I sites of pBud-EGFP or pBud-EGFP-Bax
generating pBud-EGFP/PrP mutants or pBud-EGFP-Bax/PrP
mutants.
Transfections
Human neurons (1.5610
5 cells) plated onto poly-L-lysine-
coated plastic coverslips and MCF-7 cells (2.5610
5 cells) plated
onto glass coverslips were transfected with the Helios Gene Gun
system (Bio-Rad, Mississauga, ON, Canada) at a shooting pressure
of 100 psi for human neurons and 220 psi for MCF-7 cells.
Cartridges contained 1 mg DNA and 0.125 mg gold per shot
[18,31]. N2a cells (0.8610
6 cells) plated in six-well plates were
transfected with 4 mg of pBud-EGFP/PrP or/PrP mutant DNAs
using the Lipofectamine
2000 reagent (Invitrogen). To generate SP-
CyPrP, N2a cells were transfected with 10 and 20 mg of pBud-
EGFP/PrP DNA, as previously described [27].
Condensed chromatin
Twenty hours after transfection, MCF-7 cells and human
neurons were washed with phosphate-buffered saline (PBS,
150 mM NaCl, 2.7 mM KCl, 1.3 mM KH2PO4, and 8.1 mM
Na2HPO4, pH 7.4), fixed 20 min at room temperature in 4%
paraformaldehyde and 4% sucrose in PBS, and the chromatin
stained 20 min with 1 mg/mL Hoechst 33342 (Sigma-Aldrich,
Oakville, ON, Canada) in PBS. The percentage of cell death was
calculated by counting the number of EGFP-positive cells with
condensed chromatin over the total number of EGFP-positive cells
using a Nikon Eclipse TE2000-U microscope.
TUNEL
Human neurons were fixed 20 hours after transfection, as
described above, and Terminal deoxynucleotidyl transferase-
mediated dUTP nick end labeling (TUNEL) was performed with
the TM Red In Situ Cell Death Detection kit (Roche Applied
Science, Laval, QC, Canada). The percentage of TUNEL-positive
cells was obtained by counting the TUNEL- and EGFP-positive
cells over the total number of EGFP-positive cells.
Caspase activity
MCF-7 cells were labeled 20 hours after transfection for active
caspases with the SR Fluorochrome-labeled inhibitors of caspases
(FLICA) poly caspase kit (AbD Serotec, Raleigh, NC, USA). The
percentage of FLICA-positive cells was calculated by counting the
FLICA- and EGFP-positive cells over the number of total EGFP-
positive cells.
Subcellular Fractionations
N2a cells were treated 24 hours after transfection with 0.25 mM
epoxomycin (BioMol, Plymouth Meeting, PA, USA) and 5 mg/mL
Brefeldin A (BioMol) for 18 hours. Subcellular fractionation was
performed as described previously [31] using one well of a six-well
plate for each condition. To prepare samples for western blotting,
proteins from the homogenate (1/20 of one well), membranes (1/4
of one well), cytosol (1 well), and nuclei (1/4 of one well) were
precipitated with four volumes of ice-cold methanol overnight at
220uC, centrifuged at 11 5006g 15 min at 4uC, dried, and
solubilized in the Laemmli’s sample buffer (2% SDS (w/v), 5% b-
mercaptoethanol (v/v), 10% glycerol, 0.01% bromophenol blue
(w/v), and 62.5 mM Tris-HCl, pH 6.8).
Detergent solubility of CyPrP
Cytosolic proteins obtained from the subcellular fractions were
solubilized 20 min on ice in lysis buffer (150 mM NaCl, 2 mM
EDTA, 0.5% Triton X-100 (v/v), 0.5% sodium deoxycholate
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5006g for 15 min at 4uC to separate detergent-soluble proteins
(supernatant) from the detergent-insoluble proteins (pellet).
Detergent-soluble proteins were concentrated by methanol
precipitation and these as well as the detergent insoluble proteins
solubilized in the Laemmli’s sample buffer for western blotting.
Peptide-N-glycosidase F digestion
Membrane fractions from N2a cells were treated with Peptide-
N-glycosidase F (PNGase F) according to manufacturer’s instruc-
tions (New England BioLabs, Pickering, ON, Canada). Briefly,
proteins from membrane fractions were adjusted to 0.5% SDS and
1% b-mercaptoethanol, denatured 10 min at 100uC and incubat-
ed overnight at 37uC with 2 units of PNGase F in the presence of
protease inhibitors. The proteins were methanol precipitated as
described above.
Western blot analyses
The proteins were separated on 15% SDS-PAGE gels and
transferred to polyvinylidene fluoride membranes. The mem-
branes were probed with the anti-PrP 3F4 antibody [33] (1:2000),
the polyclonal antiserum directed against the N-terminal signal
peptide of PrP (SP-PrP, 1:1000, kindly provided by Dr. D.A.
Harris, Washington University School of Medicine), the mito-
chondrial heat shock protein 70 (mtHsp70, 1:10 000, clone JG1;
Affinity BioReagents, Golden, CO, USA), CHOP (also called
GADD153, 1:1000, clone B-3; Santa Cruz Biotechnology, Santa
Cruz, CA, USA), Poly-(ADP-ribose)-polymerase (PARP, 1:2000;
Roche Applied Science), Bax (1:1000, Clone N20; Santa Cruz
Biotechnology), BiP (also called GRP 78, 1:250, clone H-129;
Santa Cruz Biotechnology), GFP (1:1000, clone B-2; Santa Cruz
Biotechnology), and b-actin (1:1000, clone AC-15; Sigma-Aldrich).
Immunoreactivity was detected with anti-mouse or anti-rabbit
secondary antibodies conjugated to horseradish peroxidase (GE
Healthcare, Baie d’Urfe, QC, Canada) and chemiluminescence
reagents (Millipore, Billerica, MA, USA).
Quantitation of cytosolic and nuclear PrP
The intensity of PrP detected by western blot analyses was
resolved with the Image Quant TL software (GE Healthcare). The
ratio of cytosolic PrP over membrane PrP or the ratio of nuclear
PrP over membrane PrP was calculated.
Statistical analyses
Statistical analyses were performed with StatView software
(SAS Institute, Cary, NC, USA). To determine the statistically
significant difference, we used ANOVA followed by a post hoc
Scheffe ´ test. A p value#0.05 was considered a significant
difference. To determine the correlation coefficient and its
significance, we used the Fisher’s r to z transformation.
Results
GSS-associated PrP mutants F198S
V, D202N
V, P102L
V and
Q217R
V, but not P102L
M, P105L
V, Y145stop
M, and
Q212P
M, prevent Bax-mediated condensed chromatin in
MCF-7 cells
GSS-associated PrP mutations P105L, A117V, F198S, D202N,
and Q217R have been reported with a valine at codon 129,
whereas P102L, Y145stop, and Q212P carry a methionine at
codon 129 [1,3,34–36]. In some rare cases, P102L is associated
with a valine at codon 129 [34]. To assess if the PrP anti-Bax
function was altered in GSS mutants, specific single point
mutations with their respective methionine or valine at codon
129 into the prion protein cDNA were produced and the mutant
cDNA inserted into the bigenic pBudCE4.1 construct under the
CMV promoter (Fig. 1A). This construct also expresses either
EGFP or EGFP-Bax protein under the EF-1a promoter.
Therefore, cell death is specifically induced by over-expression
of Bax and the anti-Bax function of co-expressed wild type (WT)
PrP or PrP mutants is directly assessed. Bax overexpression
resulted in the condensation of chromatin in approximately 65%
of the transfected MCF-7 cells within 20 hrs of transfection
(Fig. 1B). Co-expression of WT PrP with either a methionine
(PrP
M) or valine (PrP
V) at codon 129 prevented Bax-mediated
condensed chromatin. Similar to our previous observations with
CJD mutants, the P102L
M, P105L
V, Y145stop
M and Q212P
M PrP
mutants completely lost their ability to prevent Bax-mediated
condensed chromatin. However, F198S
V, D202N
V, and Q217R
V
completely while the P102L
V partially retained the anti-Bax
function. None of the GSS-associated PrP mutants co-expressed
with EGFP induced chromatin condensation in MCF-7 cells,
except for the Y145stop
M which, consistent with previous
observations [37], significantly increased the number of cells with
condensed chromatin by 15% (Fig. 1B). Together, these results
indicate that only a few of the GSS-associated mutants retain PrP’s
ability to prevent Bax-mediated condensed chromatin in MCF-7
cells.
GSS-associated PrP mutants F198S
V, D202N
V, and
Q217R
V cannot inhibit Bax-mediated caspase activation
MCF-7 cells are deficient in Caspase-3 (Casp3) expression
because of a deletion in the Casp3 gene and thus cannot undergo
DNA fragmentation in apoptotic conditions [38,39]. Condensed
chromatin is dependent on the activation of Casp6 and Casp7 in
these cells. To determine if the F198S
V, D202N
V, and Q217R
V
PrP mutants completely inhibited Bax-mediated apoptosis or
simply delayed condensed chromatin formation, we measured
caspase activity with the FLICA pan-caspase substrate, SR-VAD-
fmk (Fig. 2A). Bax induced caspase activity in approximately 60%
of the cells and WT PrP
M and PrP
V inhibited caspase activation.
However, in contrast to cell death measured by condensed
chromatin, only P102L
V inhibited caspases activated by EGFP-
Bax overexpression. FLICA positive cells did not always contain
condensed chromatin (Fig. 2B). In condensed chromatin-positive
cells, Q217R
V and P102L
V, but not the F198S
V or D202N
V,
inhibited Bax-mediated caspase activation. Furthermore, D202N
V
significantly induced caspase activation in non-condensed chro-
matin cells (Fig. 2C). These results indicate that the GSS-
associated PrP mutants, F198S
V, D202N
V, and Q217R
V, simply
delay the condensation of chromatin but do not completely inhibit
Bax-mediated apoptotic pathways in MCF-7 cells.
Decreased levels of CyPrP correlate with the loss of anti-
Bax function in GSS-associated PrP mutants expressed in
MCF-7 cells
To determine if the loss of anti-Bax function from the GSS-
associated PrP mutants is due to lower levels of CyPrP as
previously shown in CJD mutants [31], transfected cells treated
with Brefeldin A to promote retrotranslocation and epoxomicin to
prevent proteasomal degradation of CyPrP, were submitted to
subcellular fractionation (Fig. 3A). Mouse N2a cells were used for
subcellular fractionations because Brefeldin A and epoxomicin
treatment of MCF-7 cells increase the expression of endogenous
human PrP and the 3F4 antibody can be used to selectively
recognize the human PrP expressed from the transfected construct
Anti-Bax Role of PrP Mutants
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nuclear fractions showed the presence of mitochondrial Hsp70
(mtHsp70) in the membrane and nuclear fraction only, the
presence of the endoplasmic reticulum (ER)-localized BiP protein
in the membranes only, and the presence of nuclear protein PARP
and nuclear-translocated protein CHOP [40] in the nuclear
fraction. Bax was detected in all fractions and EGFP was present
in the nuclear and cytosolic, but not in the membrane fractions.
The presence of mtHsp70 and Bax in the nuclear fraction, in
addition to the nuclear markers PARP and CHOP, indicates
either a contamination of the nuclear proteins or a redistribution
of these proteins into the nucleus under Brefeldin A and
epoxomicin treatment. Nevertheless, these results indicated that
the cytosolic and membrane fractions are pure and can thus be
used to assess the presence of CyPrP.
The WT PrP
M, WT PrP
V, F198S
V, D202N
V, Q217R
V and
Q212P
M PrP mutants generated detectable levels of CyPrP while
the P102L
M, P102L
V, P105L
V, and Y145stop
M did not (Fig. 3B).
The levels of PrP in the membrane, cytosolic and nuclear
subcellular fractions were then analyzed quantitatively and the
levels of CyPrP were expressed relative to the membrane PrP to
account for differences in the levels of protein expression (Fig. 3C).
Except for the Q212P
M, the mutants generating the highest levels of
CyPrP were those inhibiting Bax-mediated condensed chromatin,
whereasthosewith the lowestlevelsofCyPrPwere theonesthat had
partially or completely lost this function. The level of CyPrP
correlated significantly with their ability to prevent Bax-mediated
condensed chromatin (Fig. 3D). In contrast, the ratio of nuclear
PrP relative to membrane PrP was similar in WT and mutant PrPs
(Fig. 3E) and did not correlate with the level of condensed
Figure 1. GSS-associated PrP mutants F198S
V, D202N
V, P102L
V and Q217R
V, but not P102L
M, P105L
V, Y145stop
M, and Q212P
M,
prevent Bax-mediated condensed chromatin in MCF-7 cells. A. Schematic diagram of human PrP showing the signal peptide, the
octapeptide repeats, the transmembrane domain (TM), the b-sheets (b1 and b2), the a-helices (a1, a2, a3), the glycosyl phosphatidylinositol (GPI)-
anchor signal peptide, the polymorphic codon at amino acid 129, and the GSS PrP mutations. B. Percentage of cell death assessed by condensed
chromatin in MCF-7 cells transfected with pBud-EGFP or pBud-EGFP-Bax (control), pBud-EGFP/PrP or PrP mutants, and pBud-EGFP-Bax/PrP or PrP
mutants carrying a methionine (
M) or a valine (
V) at codon 129. Data represent the mean6SEM of six independent experiments. At least 600 cells were
counted for each condition. * and # indicate a statistically significant difference (p#0.05) compared to the control and wild type PrP, respectively.
doi:10.1371/journal.pone.0006647.g001
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correlates with loss of PrP’s anti-Bax function in MCF-7 cells.
Glycosylation profile of GSS-associated mutants does not
correlate with anti-Bax activity
Treatment with Brefeldin A prevents maturation of secretory
proteins through the Golgiapparatus,therefore only unglycosylated or
immature glycosylated forms of PrP were expected in the transfected
cells. However, the GSS PrP mutants showed differences in their
glycosylation profile (Fig. 3B). In total cellular homogenates or in the
membrane fractions, WT PrP
Mor
V, P102L
Mor
V,P105L
V,Q217R
V
showed three PrP immunoreactive protein bands, while F198S
V and
D202N
V generated two, and the Q212P
M showed only one. The
Y145stop
M showed two lower MW protein bands that cannot
represent glycosylation since the glycosylation sites are absent in this
truncated mutant. To determine if these protein bands reflected
glycosylation or truncations of the PrP mutants, the membrane
proteins were deglycosylated with PNGase F (Fig. 4). Deglycosylation
converted all mutant proteins to the 25 kDa deglycosylated PrP. In
addition, the WT PrP
M, F198S
V, Q217R
V, P102L
V and P105L
V
displayed very low levels of some 14–23 kDa MW fragments
indicating a small amount of truncated PrP. There was no correlation
between the glycosylation profile and the anti-Bax function. These
results indicate that the GSS-associated mutants are differentially
glycosylated in these transfected cells but that the glycosylation profile
does not account for the anti-Bax function of PrP.
GSS mutant CyPrPs do not aggregate
To study if CyPrP mutants aggregate, cytosolic proteins from
WT PrP or PrP mutant transfected cells were solubilized in 0.5%
Triton X-100 and 0.5% sodium deoxycholate. WT PrP
V as well as
PrP mutants F198S
V, D202N
V, Q217R
V, and Q212P
M generated
detergent soluble, but no detergent insoluble CyPrP (Fig. 4B).
The results show that CyPrP generated from GSS PrP mutants
does not aggregate in the cytosol and thus, aggregation cannot be
responsible for the loss of anti-Bax function in the GSS mutants
that generate CyPrP.
Transfection of WT PrP and GSS PrP mutants generate
some CyPrP through the pre-emptive quality control
pathway
To determine if CyPrP generated from GSS PrP mutants occurs
through the pre-emptive quality control pathway and thus has
retained its signal peptide, we performed a western blot of the
cytosolic proteins with an antibody directed against the N-terminal
signal peptide of PrP (SP-PrP) [27]. CyPrP from WT PrP
V, PrP
F198S
V, D202N
V, Q217R
V, and Q212P
M all contained a small
amount of SP-CyPrP, whereas increasing the concentration of WT
PrP cDNA to 10 or 20 mg generated easily detectable SP-CyPrP
(Fig. 4C). Given that the CyPrP easily detected with the 3F4
antibody migrates at 25 kDa, the expected size for PrP that would
have lost both its N-terminus and C-terminus signal peptides, these
results indicate that GSS PrP mutants generate considerably more
retrotranslocated CyPrP than SP-CyPrP.
All GSS-associated PrP mutants lose their anti-Bax
function in primary human neurons
To determine the anti-Bax function of GSS-associated PrP mutants
in a neuronal cell type, we assessed the ability of the GSS-associated
mutants against Bax-mediated cell death in primary human neurons.
None of the GSS-associated PrP mutants induced cell death assessed
b yc o n d e n s e dc h r o m a t i ni np r i m a r yh u m a nn e u r o n s( Fig. 5A).
However, these mutants also did not protect against Bax-mediated
Figure 2. GSS-associated PrP mutants F198S
V, D202N
V, and
Q217R
V cannot inhibit Bax-mediated caspase activation. A.
Percentage of FLICA positive MCF-7 cells transfected with pBud-EGFP-
Bax (control) or pBud-EGFP-Bax/PrP or PrP mutants. B&C .Percentage
of FLICA positive and condensed chromatin (B) or FLICA positive and
non-condensed chromatin (C) transfected MCF-7 cells. For A–C, data
represent the mean6SEM of three independent experiments. At least
300 cells were counted for each condition. * indicates a statistically
significant difference (p#0.05) compared to the control.
doi:10.1371/journal.pone.0006647.g002
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PLoS ONE | www.plosone.org 5 August 2009 | Volume 4 | Issue 8 | e6647Figure 3. Correlation of the anti-Bax activity with CyPrP levels in GSS-associated PrP mutants. A. Western blot with mitochondrial Hsp70
( m t H s p 7 0 ) ,B i p ,P A R P ,C H O P ,B a x ,G F P ,a n db-actin in protein extracts from subcellular fractions from pBud-EGFP/PrP
M-transfected N2a cells. Homogenates
(H), membrane (M), cytosol (C), and nuclear (N) protein extracts were loaded on gels as a ratio of 1:5:20:5, respectively. B. W e s t e r nb l o t so fP r Pw i t ht h e3 F 4
antibody in proteins extracted from subcellular fractions isolated from pBud-EGFP/PrP or PrP mutant-transfected N2a cells. C. Ratio of CyPrP to membrane
PrP. The data represent the mean6SEM of three to four independent experiments. * indicates a statistically significant difference (p#0.05) compared to WT
PrP. D. Correlation between the levels of CyPrP and levels of condensed chromatin. The correlation is statistically significant (p#0.05) as determined by a
Fisher’s r to z transformation. E. Ratio of nuclear PrP to membrane PrP. The data represent the mean6SEM of three to four independent experiments. F.
Correlation between the levels of nuclear PrP and levels of condensed chromatin. The correlation is not statistically significant (p=0.96).
doi:10.1371/journal.pone.0006647.g003
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compared to WT PrP’s. Because all mutants lost their ability to inhibit
the downstream Bax-mediated events, these results inferred that the
mutants were also unable to inhibit caspase activation. The cytosolic
level of GSS PrP mutants could not be assessed in these cells because
of the very low transfection efficiency and the high endogenous level of
PrP in the human primary neurons. Nevertheless, these results show
the loss of anti-Bax function in the GSS-associated PrP mutants in
human primary neurons.
Discussion
In this manuscript, we examined the anti-Bax function of GSS-
associated PrP mutants. WT PrP inhibits the first step of Bax
activation in human primary neurons and in MCF-7 cells [18]. We
previously have shown that eleven CJD-associated PrP mutants
with a methionine at codon 129, partially or completely lost their
anti-Bax function but that this loss of function could be rescued by
co-expressing the CJD mutant PrP with WT CyPrP or its cognate
mutant CyPrP [31]. We had also tested the GSS-associated
A117V mutant and determined that this mutant retained its anti-
Bax function in MCF-7 cells and in human neurons. This
suggested that GSS-associated mutants could retain their anti-Bax
function and that the retention of this protective function might be
relevant to the longer duration of GSS diseases. However, none of
the eight additional GSS PrP mutants studied here prevented Bax-
mediated DNA condensation or DNA fragmentation in primary
human neurons. Because endogenous PrP is highly expressed in
Figure 4. Characterization of the glycosylation profile, detergent solubility and type of CyPrP in GSS mutant-transfected cells. A.
Western blots of PrP in membrane fractions from pBud-EGFP/PrP or PrP mutant-transfected cells treated with or without PNGase F. B. Western blot with
3F4 anti-PrP or anti-b-actin showing detergent solubility of CyPrP from pBud-EGFP/PrP
V or PrP mutant-transfected N2a cells. S indicates detergent
soluble andI indicates detergent insolubleCyPrP. C. Western blotswith anti-SP-CyPrP andb-actinin cytosolicproteinsofN2acellstransfected with 4 mg
of pBud-EGFP/PrP
V or PrP mutants or transfected with 10 mg and 20 mg of pBud-EGFP/PrP
V as positive control for SP-CyPrP detection.
doi:10.1371/journal.pone.0006647.g004
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mutants, similar to the CJD-associated mutants, have a dominant
effect over WT PrP with respect to the anti-Bax function. We also
confirmed the loss of anti-Bax function in MCF-7 cells. These cells
do not contain detectable levels of endogenous PrP under normal
culture conditions, thus eliminating possible effects of endogenous
PrP [14]. In the MCF-7 cells, P102L
M, P105L
V, Y145stop
M, and
Q212P
M could not inhibit Bax-mediated condensed chromatin.
However, four of the GSS-associated mutants, F198S
V, D202N
V,
P102L
V and Q217R
V, prevented Bax-mediated condensed
chromatin. However, except for the P102L
V, these mutants did
not inhibit caspase activation, a step that is upstream of chromatin
condensation in the Bax-activated death pathway. The results
indicated that these mutants simply delayed the cell death pathway
because, in addition to the caspase activation in condensed
chromatin positive cells, some transfected cells showed caspase
activation in non-condensed chromatin positive cells. In contrast
to human neurons, the MCF-7 cells lack the Casp3 gene and thus
do not undergo DNA fragmentation although condensation of
chromatin occurs through Casp6 and Casp7 activation [38,39].
The difference in cell death pathways is likely the reason for the
slight difference in the results between MCF-7 cells and human
neurons. Therefore, we conclude from the results in human
neurons and in MCF-7 cells that the anti-Bax function of PrP
mutants is not associated with the long duration of the GSS prion
disease.
We also show in this paper that the loss of GSS mutants in
inhibiting Bax-mediated condensed chromatin results from the
inability of these mutants to generate CyPrP in MCF-7 cells. As
shown previously with the eleven CJD-associated PrP mutants
[31], the level of CyPrP generated from the GSS-associated
mutants was inversely proportional to the level of Bax-mediated
condensed chromatin in MCF-7 cells. We observed severely
depressed CyPrP levels in P102L
V/M, P105L
V, Y145stop
M. The
results with PrP Y145stop are consistent with others that show that
PrP Y145stop has a short half-life and accumulates in the nucleus,
ER, and Golgi but not significantly in the cytosol [44,45]. We also
observed weak levels of Y145stop
M mostly in the nuclear fraction.
In those mutants that did generate detectable CyPrP, most of the
CyPrP likely resulted from retrotranslocation because CyPrP
migrated at the expected size for deglycosylated PrP lacking the N-
terminal or C-terminal signal peptides. Retention of the signal
peptides would show a protein migrating at 28 to 30 kDa rather
than at 23–25 kDa as we observe. Furthermore, western blots of
CyPrP with anti-signal peptide antiserum gave only a weak signal
compared to that obtained with the anti-PrP 3F4 antibody. The
anti-Bax function could have been influenced also by the
aggregation of CyPrP, a condition detected in GSS mutants
expressed in other cell types [41,42,46]. However, we did not
observe any detergent insoluble CyPrP indicating that aggregation
was not significant in our experimental conditions. The inability of
the Q212P mutant to prevent Bax-mediated condensed chroma-
tin, despite generating significant levels of CyPrP (our results and
[41]), was consistent with our previous studies showing that proline
disruption of PrP’s helix 3 structure inhibits PrP’s anti-Bax
function [30]. The consequences of defective retrotranslocation or
loss of the pre-emptive quality control pathway in these mutants
will need to be examined more closely. It is generally assumed that
familial PrP mutations affect the folding and the stability of the
mutants compared to WT PrP and this has been experimentally
demonstrated for P102L, F198S, and Q217R PrP mutants in vitro
and in vivo studies [42,46–53]. We have shown that CJD mutants
accumulate to normal levels on the cell surface while undergoing
defective retrotranslocation [31]. Several signaling functions are
attributed to cell surface PrP and could be affected by misfolded
mutant PrP that have escaped the retrotranslocation or the pre-
emptive quality control pathways [54–57].
Figure 5. All GSS-associated PrP mutants lose their anti-Bax
function in primary human neurons. A. Percentage of cell death
assessed by condensed chromatin in human neurons transfected with
pBud-EGFP or pBud-EGFP-Bax (control), pBud-EGFP/PrP or PrP mutants,
and pBud-EGFP-Bax/PrP or PrP mutants carrying a methionine (
M)o ra
valine (
V) at codon 129. Data represent the mean6SEM of three
independent experiments. At least 300 cells were counted for each
condition. * indicates a statistically significant difference (p#0.05)
compared to the control. B. Percentage of apoptotic cells displaying
DNA fragmentation assessed by TUNEL in human neurons transfected
with pBud-EGFP-Bax (control), pBud-EGFP-Bax/PrP, or pBud-EGFP-Bax/PrP
mutants. Data represent the mean6SEM of three independent experi-
ments. At least 150 cells were counted for each condition. * indicates a
statistically significant difference (p#0.05) compared to the control.
doi:10.1371/journal.pone.0006647.g005
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that generated significant levels of CyPrP and prevented
condensed chromatin could not prevent caspase activation.
Therefore, the CyPrP generated from these GSS-associated PrP
mutants did not have normal anti-Bax function. Indeed, the
F198S
V, Q217R
V, and D202N
V mutants generated as much
CyPrP as WT PrP
V and while this level was sufficient in
preventing Bax-mediated caspase activation in WT PrP, it was
not in mutant PrPs. Others have shown that PrP Q217R
V escapes
the ER quality control and accumulates as an abnormally folded
form in the post-Golgi compartment of neuroblastoma cells [42].
Consistent with our observations, a portion of PrP Q217R
V
accumulates in the cytosol [43]. Because we have previously
demonstrated that CyPrP is the main form of PrP with the anti-
Bax function [26], we conclude that the mutant CyPrP generated
from these three mutants are less efficient at inhibiting the Bax
activation pathway than the WT PrP. Previously, we have shown
that the helix 3 is necessary and sufficient to inhibit Bax-mediated
cell death [30]. The F198S
V, Q217R
V, and D202N
V location in
helix 3 is consistent with the observed loss of anti-Bax function in
these mutants, despite their ability to generate CyPrP. Therefore,
the loss of anti-Bax function in PrP mutants can occur through two
mechanisms: low levels of CyPrP through decreased retro-
translocation or pre-emptive quality control and loss in anti-Bax
activity for those mutants that can generate CyPrP.
We found it interesting to observe significant amounts of PrP in
the nuclear fraction from Wt PrP and most mutant PrP-transfected
cells. We can exclude the possibility of contaminating endoplasmic
reticulum membranes in the nuclear fraction since BiP is not
detected in the nuclear proteins. Possibly, nuclear PrP was
translocated from the cytosol to the nucleus. Others have reported
fluorescent-tagged PrP and C-terminally truncated forms of PrP in
the nuclear and perinuclear compartments [44,45,58–60]. Nuclear
localization was also observed for CyPrP generated by alternative
initiation of translation [61]. Two independent nuclear localiza-
tion signals (NLS) in full length PrP were proposed [58] but CyPrP
translocates to the nucleus independently of these two NLS [62].
The nuclear PrP possibly occurs only under stress conditions [58].
Interestingly, PrP interacts with DNA, RNA [63,64], and
chromatin [62,65] and may be involved in a yet unidentified
function in the nuclear compartment. Once this function is
determined, it will be interesting to assess the effect of nuclear
mutant PrP. However, the level of nuclear PrP did not correlate
with the level of condensed chromatin and thus is unlikely to be
involved in the anti-Bax function.
In conclusion, we have excluded the possibility that the
retention of PrP’s anti-Bax function in GSS-associated mutants
could be responsible for the longer duration of GSS disease
relative to CJD. However, the fact that nineteen different single
point mutations of the prion protein associated with CJD, GSS
and FFI significantly inhibit PrP’s anti-Bax function suggests that
both trafficking and structural problems arise with mutations in
the PrP.
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